Study summary
Sac-TMT shrank tumors in nearly half of heavily treated patients
6.7months without progression, vs 2.5 with chemotherapy
What was tested
Sacituzumab tirumotecan (sac-TMT), another TROP2 antibody-drug conjugate, against chemotherapy after two or more earlier treatments. Run in China.
What they found
- Median progression-free survival was 6.7 vs 2.5 months.
- Tumors shrank in 45.4% vs 12.0%.
- Low blood counts were the most common side effect.
What it means
Merck is now testing sac-TMT worldwide, including after surgery.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.